AbbVie 8-K Details Financial Condition, Senior Notes on Feb 2
Ticker: ABBV · Form: 8-K · Filed: Feb 2, 2024 · CIK: 1551152
| Field | Detail |
|---|---|
| Company | Abbvie Inc. (ABBV) |
| Form Type | 8-K |
| Filed Date | Feb 2, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: financial-condition, debt, corporate-filing
TL;DR
**AbbVie just dropped an 8-K with fresh financial results and debt info, so check it out.**
AI Summary
AbbVie Inc. filed an 8-K on February 2, 2024, reporting on its results of operations and financial condition. This filing indicates that AbbVie is providing updated financial information, including details on various senior notes such as the 1.375% Senior Notes due 2024 and 2.125% Senior Notes due 2029. This matters to investors because it provides current financial health and operational performance data, which can influence stock valuation and future dividend decisions.
Why It Matters
This filing provides investors with the latest financial and operational data for AbbVie, crucial for assessing the company's health and making informed investment decisions.
Risk Assessment
Risk Level: low — This 8-K is a routine disclosure of financial information and does not indicate any immediate new risks.
Analyst Insight
A smart investor would review the full financial statements and exhibits referenced in this 8-K to understand the specifics of AbbVie's operational results and debt structure, especially concerning the senior notes maturing in 2024, to assess the company's liquidity and financial stability.
Key Numbers
- 2024-02-02 — Date of Report (The earliest event reported in the 8-K filing.)
- 1.375% — Interest Rate (Rate for AbbVie's Senior Notes due 2024.)
- 2024 — Maturity Year (Maturity year for 1.375% and 1.250% Senior Notes.)
- 2027 — Maturity Year (Maturity year for 0.750% Senior Notes.)
- 2028 — Maturity Year (Maturity year for 2.125% and 2.625% Senior Notes.)
- 2029 — Maturity Year (Maturity year for 2.125% Senior Notes.)
- 2031 — Maturity Year (Maturity year for 1.250% Senior Notes.)
Key Players & Entities
- AbbVie Inc. (company) — the registrant filing the 8-K
- Delaware (company) — state of incorporation for AbbVie Inc.
- North Chicago, Illinois (company) — principal executive offices of AbbVie Inc.
- 001-35565 (dollar_amount) — Commission File Number
- 32-0375147 (dollar_amount) — IRS Employer Identification No.
- 1.375% (dollar_amount) — interest rate for Senior Notes due 2024
- 1.250% (dollar_amount) — interest rate for Senior Notes due 2024 and 2031
- 0.750% (dollar_amount) — interest rate for Senior Notes due 2027
- 2.125% (dollar_amount) — interest rate for Senior Notes due 2028 and 2029
- 2.625% (dollar_amount) — interest rate for Senior Notes due 2028
Forward-Looking Statements
- AbbVie will continue to manage its debt obligations effectively as its 2024 senior notes mature. (AbbVie Inc.) — high confidence, target: 2024-12-31
- The detailed financial condition report will provide a stable outlook for AbbVie's stock performance in the near term. (AbbVie Inc.) — medium confidence, target: 2024-06-30
FAQ
What is the purpose of AbbVie Inc.'s 8-K filing dated February 2, 2024?
The 8-K filing by AbbVie Inc. on February 2, 2024, is a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, specifically reporting on 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits'.
What specific financial instruments are mentioned in the filing with their respective interest rates and maturity dates?
The filing mentions several senior notes, including 1.375% Senior Notes due 2024, 1.250% Senior Notes due 2024, 0.750% Senior Notes due 2027, 2.125% Senior Notes due 2028, 2.625% Senior Notes due 2028, 2.125% Senior Notes due 2029, and 1.250% Senior Notes due 2031.
What is AbbVie Inc.'s business address and phone number as stated in the filing?
AbbVie Inc.'s business address is 1 North Waukegan Road, North Chicago, Illinois 60064-6400, and its telephone number is (847) 932-7900.
What is the Central Index Key (CIK) for AbbVie Inc.?
The Central Index Key (CIK) for AbbVie Inc. is 0001551152.
Under which SEC Act was this 8-K form filed?
This 8-K form was filed under the 1934 Act.
Filing Stats: 504 words · 2 min read · ~2 pages · Grade level 9 · Accepted 2024-02-02 07:51:16
Key Financial Figures
- $0.01 — ange on which registered Common Stock, $0.01 Par Value ABBV New York Stock Exchange
Filing Documents
- abbv-20240202.htm (8-K) — 40KB
- abbv-20231231xexhibit991.htm (EX-99.1) — 488KB
- logoabbviea06.gif (GRAPHIC) — 3KB
- 0001551152-24-000007.txt ( ) — 784KB
- abbv-20240202.xsd (EX-101.SCH) — 4KB
- abbv-20240202_def.xml (EX-101.DEF) — 20KB
- abbv-20240202_lab.xml (EX-101.LAB) — 41KB
- abbv-20240202_pre.xml (EX-101.PRE) — 21KB
- abbv-20240202_htm.xml (XML) — 10KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition On February 2, 2024, AbbVie Inc. issued a press release announcing financial results for the fourth quarter and full year ended December 31, 2023. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Exhibit 99.1 Press Release dated February 2, 2024 (furnished pursuant to Item 2.02). 104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABBVIE INC. Date: February 2, 2024 By: /s/ Scott T. Reents Scott T. Reents Executive Vice President, Chief Financial Officer